AIM ImmunoTech Inc (NYSE:AIM) announced that it has entered into a lease agreement with the New Jersey Economic Development Authority for a 5,210 square foot research and development (R&D) facility at the state-supported New Jersey Bioscience Center (NJBC).
The immuno-pharma company said the incubator at North Brunswick, New Jersey, which is designed for small businesses in the region, is dedicated to life sciences and biotechnology companies, and the NJBC has invested over $70 million in facilities and improvements to its campus.
“This state-of-the-art facility will help us to continue to advance our research and development of Ampligen to treat multiple types of cancers, immune disorders, and viral diseases,” AIM ImmunoTech CEO Thomas Equels said in a statement.
READ: AIM ImmunoTech boosts intellectual property with new Netherlands utility patent covering Ampligen and dsRNA products aimed at COVID-19
“We have made a significant investment in new equipment for this facility and believe that this space will enhance our future development progress,” Equels added.
Based in Ocala, Florida, AIM ImmunoTech is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral disorders, including COVID-19.
Contact Sean at sean@proactiveinvestors.com